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Abstract
Goals: The main purpose of this study is to broaden the clinicopathological spectrum and increase recognition of
follicular dendritic cell sarcoma (FDCS) through analysis of the clinical and pathological features of 50 cases.
Methods: The clinicopathological features of total 50 cases of FDCS were analyzed including a review of 44 cases
reported in Chinese literature before October 2009 and six original cases from the pathology files conducted by
the authors.
Results: The youngest patient came under observation in this study is only seven years old. Including the cases
contributed by the authors, our literary review indicated that male dominated the tumor cases (M: F = 3: 2). 28
cases (56%) present with this disease in extranodal sites. Tumor cells demonstrated positive staining for the
follicular dendritic cell markers CD21 (47/49), CD35 (43/45), CD23 (20/23) and CD68 (23/25). In situ hybridization for
Epstein-Barr virus-encoded RNA was performed in 10 cases. Nevertheless, EBV expression was absent in all these
cases. The follow-up analysis of all cases shows that 26 (81.2%) patients were alive and disease free; 6 (18.8%)
patients were alive with recurrent disease or metastasis; and nobody had died of this disease at the time of last
follow-up.
Conclusions: The diagnosis of the FDCS is based on the findings of morphology and immunohistochemistry. The
FDCS occurred in China should be viewed and treated as a low-grade sarcoma, and the role of the EBV in the
pathogenesis of this tumor is still uncertain. There is a possibility that the tumor might be racial or geographic
correlated, because most cases were reported from Eastern Asia area; it’s particular the case of the liver or spleen
tumor.
Introduction
Classified as accessory cells of the immune system, the
follicular dendritic cells (FDC), also known as dendritic
reticulum cells, are essential for the function of antigen
presentation and germinal center reaction regulation.
Follicular dendritic cell sarcoma (FDCS) is an uncom-
mon tumor that usually arises in lymph nodes, especially
in the cervical, mediastinal, and axillary areas, but also
in extranodal sites. The existence of a primary neoplasm
of the follicular dendritic cell was first recognized in
1986 by Monda et al [1]; since then, scattered cases
have been reported in literatures. Approximately 150
cases have been reported in English literature so far.
The scarcity may be partially due to under-recognition
of this entity. In recent years there has been an increas-
ing interest in this specific type of neoplasm due to the
emerging availability of specific antibodies that can con-
firm the FDC lineage.
To add to the existing literature on FDCS to deepen
the understanding of the disease, we analyzed the clini-
cal characteristics, pathologic features, immunophenoty-
pic profile, treatments and outcome of 50 cases
including our 6 cases and 44 cases from reviewing the
Chinese literatures on the FDCS.
Materials and methods
The present study included a total of 50 patients with
FDCS. Having not been reported previously, the first 6
cases were retrieved from the pathological files of the
Department of Pathology, Xiangya Hospital of Central
South University between 2004 and 2009. The other
cases were obtained through the major indexed
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Infrastructure) between 1994 and 2009 by searching the
key words like dendritic cell, follicular dendritic cell,
and sarcoma. The clinical characteristics of all cases of
FDCS were summarized in additional file 1.
Routine histopathological and immunohistochemical
analyses were performed from formalin-fixed, paraffin-
embedded specimens. The panel of antibodies mainly
included CD21, CD35, CD23, CD68, CD20, EMA,
Vimentin, S-100 protein, Clusterin, and LMP-1. All the
antibodies were products of DAKO and staining was
performed with the DAKO En Vision Kit. The sections
were developed with 3,3’-diaminobenzidine tetrahy-
drochloride and counterstained with hematoxylin.
In situ hybridization for Epstein-Barr virus (EBV)
-encoded RNA (EBER) was performed on paraffin sec-
tions using an EBER in situ hybridization and detection
kit (DAKO), and the staining procedure was precisely
done as recommended by the manufacturer. EBV-asso-
ciated nasopharyngeal carcinoma was served as positive
control.
Results
Clinical features
The present study contains 30 males and 20 females.
The mean age of the patients was 44 years, ranging
from 7 to 75. The 7 years old patient was the youngest
observed so far. The constitutional symptoms, including
low-grade fever, weight loss, epigastralgia, abdominal
fullness, slight anemia, and so on, were nonspecific in
patients with FDCS. Patients often presented with a
slow-growing, well-circumscribed, painless mass. One
case was complicated by Castleman’s disease, which was
discovered in chest wall. Of all cases summarized in this
review, the most common site of tumor involvement
was lymph node, for 22 cases (44%). The others (28,
56%) were located in extranodal sites, including liver (5),
gastrointestinal tract (5), nasal pharynx (5), spleen (4),
parotid gland (2), greater omentum (2), cavitas pelvis
and abdominal cavity (2), tonsil (1), adrenal gland (1),
and chest wall (1).
pathologic features
Morphological findings
The gross measurements of this tumor varied from case
to case, ranging from 0.6 to 21 cm. Macroscopically, the
tumor was characteristically well circumscribed or even
had a capsule. It was soft to slightly firm and might con-
tain areas of necrosis and hemorrhage. Microscopically,
the tumor was composed of oval to spindle cells, regard-
less of the sites of involvement, arranging in storiform,
whorled, and fasciclar patterns (Figure 1). Individual
cells possessed characteristic features, including slightly
eosinophilic, fibrillary cytoplasm, a delicate nuclear
membrane, vesicular nuclei, small but distinct nucleoli
and indistinct cell borders with occasionally multinu-
cleated forms (Figure 2). A common and highly charac-
teristic feature was the sprinkling across the entire
tumor of small lymphocytes, occasionally leading to a
misdiagnosis of lymphoma. The lymphocytes sometimes
also showed cuffing around the blood vessels. The giant
cells and mitotic figures were identified occasionally
(Figure 3). Irregular hemorrhage and coagulative necro-
sis were observed in some cases.
Three out of nine cases that involves the liver and
spleen were distinct in that they often had histological
features resembling inflammatory pseudotumor[2-4]. In
these cases, the spindle cells were dispersed in
Figure 2 Case 1 FDCS of the tonsil, individual cells possess
characteristic features, including a delicate nuclear membrane,
vesicular nuclei, small but distinct nucleoli and indistinct cell
borders. (H&E stain).
Figure 1 Case 1 FDCS of the tonsil, the spindle cells are
arranged in a storiform and whorled patterns. (H&E stain).
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tic infiltrate(Figure 4).
Immunophenotypic findings
Immunohistochemically, the FDCS exhibited unique his-
tological immunophenotypic features (Figures 5 and 6).
Tumor cells demonstrated positive staining for the folli-
cular dendritic cell markers CD21 (49/49), CD35 (43/
45), CD23 (20/23), CD68 (23/25), Vimentin (22/28), and
18 cases showed immunostaining for S-100 protein.
Positive staining for EMA was observed in 16 cases.
EBV-latent membrane protein (LMP-1) only showed
positive staining in 1 of 7 cases[5]. Other positive but
uncommon immunohistochemical markers included
HLA-DR, SMA, Clusterin, NSE and LCA.
Ultrastructural findings
Electron microscopic examination was available in 4
cases in published literature [6-8]. Tumor cells, admixed
with numerous inflammatory cells, demonstrated elon-
gated nuclei and often with finely dispersed chromatin.
Scattered lysosomes and well-developed Glogi were
noted in some cells. The most distinctive feature, how-
ever, was numerous long, slender cytoplasmic processes
joined by mature desmosomes.
EBER in situ hybridization
In situ hybridization for Epstein-Barr virus (EBV)-
encoded RNA was performed in 10 cases. Nevertheless,
EBV expression was absent in all these cases[2,9,10].
Treatment and outcome
Although various treatments including surgery, che-
motherapy, radiation therapy, and combinations of these
Figure 3 Case 3 FDCS of the liver, the giant cells and mitotic
figures are identified occasionally. (H&E stain).
Figure 4 Case 4 FDCS of the lymph node, the spindle cells are
dispersed in distribution, scattered by a prominent
lymphoplasmacytic infiltrate (H&E stain).
Figure 5 Case 1 FDCS of the tonsil, the tumor cells are
immunoreactive with CD21 strongly and diffusely.
Figure 6 Case 4 FDCS of lymph node, the tumor cells were
positive for CD35 strongly and diffusely.
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still the mainstay of treatment for primary FDCS for
most patients. In all 50 cases studied in this paper, the
patients were all treated by surgical excision, while adju-
vant radiotherapy or chemotherapy was supplemented
in 13 cases. Follow-up information was available in 32
patients, with a time interval ranging from 1 month to 5
years. Twenty-six (81.2%) patients were alive and disease
free after the treatment, 6 (18.8%) patients were alive
with recurrent disease or metastasis, and nobody had
died of this disease at the time of the last follow-up.
Discussion
FDCS is an extremely rare tumor and has been recog-
nized with increasing frequency. Most of the data on
FDCS are based on case reports or small case series
since the first report in 1986. In recent years, FDCS is
receiving increasing attention because of the availability
of more sensitive markers to confirm the FDC lineage.
Interestingly, there is a possibility that the tumor has a
race-or geographic-correlation, because 17 cases were
from Japan among the worldwide 50 cases reviewed in
our study, despite the fact that accurate information
regarding ethnic and living environment of the patients
were not available[11]. The tumor was thought to
mainly affect lymph nodes, with cervical and axillary
regions being the most common sites. However, more
than half of the reported cases in our review have been
located in extranodal sites, including palate, pharynx,
t o n s i l ,t h y r o i d ,m e d i a s t i n u m ,s p l e e n ,g a s t r o i n t e s t i n a l
tract, liver[2-10,12-32]. Therefore, FDCS presenting in
extranodal sites are worthy of more attention than ever.
At present, there is no definite etiology for most cases
of FDCS. Cytogenetic abnormalities have been described
in one case of FDCS in the spleen[33], displaying multi-
ple clonal unbalanced chromosomal translocations,
including loss of Xp. It was proposed this finding might
be early evidence of the role of Xp in the development
of this tumor. Interestingly, Castleman
’sd i s e a s eh a s
been found in association with FDCS for a minority of
case[26,34], which suggests that it may represent a pre-
cursor lesion. FDC proliferation and dysplastic changes
occurring in Castleman
’s disease can form the back-
ground from which a FDCS develops. Perhaps the
tumor arises through the sequence of hyperplasia-dys-
plasia-neoplasia. However, with only one patient pre-
sented FDCS complicated by Castleman’s disease in our
study[26], additional studies will be required to decide
whether there is a relationship between Castleman’s dis-
ease and FDCS. A possible role for p53 in the transfor-
mation process has also been proposed [35], with
overexpression of p53 protein noted in FDCS as well as
an increased number of weakly p53-positive spindle
cells in a hyaline-vascular Castleman
’s disease specimen.
EBV has been documented to be positive in a small
percentage of FDCS cases[36]. It is no wonder that
FDCS shows association with this virus because FDCS
expresses CD21 (EBV receptor) and can be experimen-
tally infected by EBV. In the 6 cases conducted by our
own team, however, we didn’t detect evidence of the
virus by in situ hybridization for EBER-1 gene. Although
the association of FDCs tumor with EBV seems to vary
in different organs, FDCS of liver seems to be strongly
presented in a peculiar way. These differentiated fea-
tures have also been noted in splenic follicular dendritic
cell tumors [37]. Thus, the role of EBV remains unclear
in the pathogenesis of FDCS tumors. Longer follow-up
of more patients is necessary to better define the charac-
teristics of this peculiar tumor. Latent membrane pro-
tein-1(LMP-1) is an integral membrane protein, and is
encoded by the LMP-1 gene of EBV. LMP-1 is consid-
ered to be a viral oncogene because of its capacity to
transform rodent fibroblasts in vitro and render them
tumorigenic in nude mice[38]. However, only one case
in our literature review shows positive staining for
LMP-1. Therefore, the clinicopathological significance of
the LMP-1 gene in FDCS tumors warrants further inves-
tigation due to the fact that only a small amount of clin-
icopathological data has been documented so far.
The pathologic characteristics and immunophenotypic
profile of FDCS in our series are similar to those in the
literature. The most common histological feature is the
presence of oval to spindle cells with elongated nuclei,
delicate, dispersed chromatin and pale eosinophilic cyto-
plasm. Lymphocytes may gather around blood vessels,
creating a cuffing pattern. Concentric whorl is also a
characteristic growth pattern. Scattered multinucleated
tumor cells may also be present. All these various mor-
phologic features must be considered in the differen-
tiated diagnosis of FDCS.
To Sum up the literature, CD21 and CD35 are the
most widely used markers. Other useful markers are
vimentin, CD23, CD68, S-100 protein, fascin, Ki-M4p
and Ki-FDC1p; however, these are unspecific. FDCS typi-
cally lacks expression of CD1a, desmin and CD45, which
allows their differential diagnosis with interdigitating
dendritic cell tumors, Langherhans cell tumors, histiocy-
tic and lymphoid neoplasias. So the expression of non-
typical FDCS markers should be taken into account in
the differential diagnosis with other neoplasms.
The diagnosis of FDC tumor is established basing on
the findings of morphology and immunohistochemistry.
Ultrastructural studies may be helpful but are not indis-
pensable for accurate diagnosis. All neoplasms in the
differential diagnosis lack follicular dendritic cell differ-
entiation and are easily excluded if FDCS is considered
and immunohistochemical staining with FDC markers is
applied.
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due to the limited experience. Current best-available
approach is to apply therapeutic guidelines similar to
those used for soft tissue sarcomas of high grade. Our
study does show some trends though. Both the analytic
literature review and the cases conducted by ourselves
suggest that FDCS can be effectively treated by surgery
and no radiotherapy or chemotherapy after radical exci-
sion is required.
Lymph nodes, lung, and liver are the most common
sites for metastasis. In case studies conducted by our
own team members, the clinical course of follicular den-
dritic cell sarcomas is akin to that of low-grade tumors.
These figures are probably underestimates, because
many cases in the literature had short follow-up periods.
To conclude, FDCS is an extremely rare tumor of
lymph nodes and extranodal tissues. Because of the
scarcity of the identified cases, it is probably under
recognized, particularly when happened in extranodal
sites. Recently, the diagnosis accuracy has been signifi-
cantly improved, thanks to the aid of IHC analysis and
the two most reliable FDC markers CD21 of and CD35.
Once FDCS is suspected histologically, immunohisto-
chemical stains for follicular dendritic cell differentiation
should be performed to avoid the risk of misdiagnosis.
As noted previously, FDCS occurring in the liver or
spleen may represent a variant subset that differs from
the FDCS in other sites, producing a histological picture
similar to inflammatory pseudotumor(IPT). They prob-
ably have different characteristics and causes. So it is
important to consider the possibility of an IPT-like FDC
tumor when making a diagnosis of a hepatic/splenic
IPT-like lesion.
FDCS has a slight recurrent and metastatic potential
and it should be viewed as a low-grade malignancy. Lit-
erature shows that therapeutic modalities in this disease
varied widely although complete surgical resection was
often included. In addition, adjuvant chemotherapy and
radiotherapy may be utilized; but the value of these
adjuvant treatments to effectively improve survival rates
has not been convincingly demonstrated.
M o s to ft h ed a t ao nF D C Sa r eb a s e do ns i n g l ec a s e
report or small-group case series, further investigations
are required to address the following questions: (1)
more systematic data are needed to understand the role
of the EBV in the pathogenesis of this tumor. (2)
Further detailed cytogenetic studies of FDCS might
reveal a specific chromosomal profile of these tumors,
which in turn will yield new insights into the biology of
FDCS and provide the pathologist with independent
genetic markers. (3) additional studies needed to decide
whether Asians would be susceptible to this disease.
Additional material
Additional file 1: The clinical characteristics of 50 cases of FDCS.T h e
clinical characteristics of all cases of FDCS were summarized in additional
file 1.
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